TMCnet News
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Oasmia Pharmaceutical AB and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmThe Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oasmia Pharmaceutical AB ("Oasmia" or "the Company") (NASDAQ: OASM) for violations of ยงยง10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oasmia disclosed on July 9, 2019, the termination of its "engagement and cooeration" with former executive chairman Julian Aleksov. The termination came after a tax audit revealing missing funds related to suspicious transactions between Oasmia and companies controlled by Aleksov and his family members. The Company reported this matter to the Swedish Economic Crime Authority. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA (News - Alert) 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected]. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005558/en/ |
